

December 23, 2025

To

The Corporate Relations Department BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

Code: 540222

To

**The Listing Department** 

National Stock Exchange of India Ltd.,

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

Mumbai – 400 051

**Code: LAURUSLABS** 

Sub: Further investment in Laurus Bio Private Limited under Regulation 30(7) of SEBI (LODR) Regulations, 2015

Ref: Our intimation letter dated 06th December, 2024

Dear Sir / madam,

In continuation to our letter dated December 06, 2024 with regard to the investment in Laurus Bio Private Limited ("Laurus Bio") (a subsidiary of Laurus Labs Ltd "Company") and as per Regulation 30(7) of SEBI (LODR) Regulations, 2015, we would like to inform you that the Company has invested **INR 34,99,87,919.74/-** (Indian Rupees Thirty Four Crores Ninety Nine Lakhs Eighty Seven Thousand Nine Hundred and Nineteen and Paise Seventy Four Only) and acquired 13,487 (Thirteen Thousand Four Hundred and Eighty Seven) Series A3 Compulsorily Convertible Preference Shares of Laurus Bio at face value of INR 100/- and premium of INR 25,850.02/- each aggregating to an amount of INR 34,99,87,919.74/- (Indian Rupees Thirty Four Crores Ninety Nine Lakhs Eighty Seven Thousand Nine Hundred and Nineteen and Paise Seventy Four Only) by way of Private Placement cum Preferential Allotment basis.

Upon this additional investment, the shareholding of the Company in Laurus Bio is 75.61% on fully diluted basis.

Please take the above information on record.

Yours faithfully,

For Laurus Labs Limited

## G. Venkateswar Reddy

Company Secretary & Compliance Officer

CIN: L24239AP2005PLC047518